What they were paid
Celldex Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $60,431 | $0 | $221,517 | $0 | $281,948 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Celldex Therapeutics, Inc. DEF 14A filed April 29, 2026, accession 0001104659-26-050884, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Celldex Therapeutics pays directors a $48,000 cash retainer and $221,517 in Stock Options.
Committees
FY2025 · as the proxy prints themCompensation · Science and Commercialization (Chair)
The rest of the Celldex Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Anthony S. Marucci | Director | $0 |
| Denice Torres | Independent Director | $480,451 |
| Garry A. Neil, M.D | Independent Director | $284,445 |
| Harry H. Penner, Jr | Chair of the Board | $296,939 |
| Herbert J. Conrad | Independent Director | $279,451 |
| James J. Marino | Independent Director | $294,434 |
| Keith L. Brownlie | Independent Director | $289,439 |
| Rita I. Jain, M.D | Independent Director | $279,451 |
The full Celldex Therapeutics compensation record
free company briefThis page is one director within Celldex Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat